BACKGROUND AND PURPOSE: Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO. METHODS:250 cryptogenic stroke patients fromPICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). RESULTS: Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%). CONCLUSIONS: In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.
RCT Entities:
BACKGROUND AND PURPOSE:Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic strokepatients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic strokepatients with PFO. METHODS: 250 cryptogenic strokepatients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic strokepatients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). RESULTS: Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%). CONCLUSIONS: In this exploratory analysis, the presence of PFO in the younger cryptogenic strokepatients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.
Authors: Scott E Kasner; Balakumar Swaminathan; Pablo Lavados; Mukul Sharma; Keith Muir; Roland Veltkamp; Sebastian F Ameriso; Matthias Endres; Helmi Lutsep; Steven R Messé; J David Spence; Krassen Nedeltechev; Kanjana Perera; Gustavo Santo; Veronica Olavarria; Arne Lindgren; Shrikant Bangdiwala; Ashkan Shoamanesh; Scott D Berkowitz; Hardi Mundl; Stuart J Connolly; Robert G Hart Journal: Lancet Neurol Date: 2018-09-28 Impact factor: 44.182